Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

F Pichon

Showing results (31-40 of 74) with videos related to

Pageof 8
Sort By:
Anticancer Research|May 16, 2000
Serum bFGF (basic fibroblast growth factor) and CA 15.3 in the monitoring of breast cancer patientsM F Pichon, G Moulin, C Pallud, et al.
Archives of Orthopaedic and Traumatic Surgery. Archiv Fur Orthopadische Und Unfall-Chirurgie|August 30, 1978
Experimental spinal cord sectionsR Roy-Camille, J M Derlon, G Saillant, et al.
Neuro-Chirurgie|January 1, 1978
[Experimental transection of the spinal cord (author's transl)]J M Derlon, R Roy-Camille, G Saillant, et al.
Cancer Research|April 15, 1990
Monoclonal antibodies against native ant denatured forms of estrogen-induced breast cancer protein (BCEI/pS2) obtained by expression in Escherichia coliJ F Prud'homme, A Jolivet, M F Pichon, et al.
European Journal of Gynaecological Oncology|February 26, 1998
Cancer of the uterine cervix: sensitivity and specificity of serum Cyfra 21.1 determinationsN Callet, C C Cohen-Solal Le Nir, E Berthelot, et al.
The Pediatric Infectious Disease Journal|November 5, 1998
Pathogens isolated during treatment failures in otitisP Gehanno, L N'Guyen, M Derriennic, et al.
The International Journal of Biological Markers|January 11, 2003
Prognostic value of CA 15.3 kinetics for metastatic breast cancerB De La Lande, K Hacene, J L Floiras, et al.
The International Journal of Biological Markers|April 14, 2004
Serum HER-2 extracellular domain: relationship with clinicobiological presentation and prognostic value before and after primary treatment in 701 breast cancer patientsM Saghatchian, S Guepratte, K Hacene, et al.
The Journal of Infectious Diseases|May 1, 1989
In vivo selection of a cephamycin-resistant, porin-deficient mutant of Klebsiella pneumoniae producing a TEM-3 beta-lactamaseB Pangon, C Bizet, A Buré, et al.
Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine|October 29, 2000
Comparison of Cyfra 21-1 and SCC assays in head and neck tumoursA Banal, K Hacene, E Berthelot-Ruff, et al.
Pageof 8

Showing results (31-40 of 74) with videos related to

Sort By:
Pageof 8
Anticancer Research|May 16, 2000
Serum bFGF (basic fibroblast growth factor) and CA 15.3 in the monitoring of breast cancer patientsM F Pichon, G Moulin, C Pallud, et al.
Archives of Orthopaedic and Traumatic Surgery. Archiv Fur Orthopadische Und Unfall-Chirurgie|August 30, 1978
Experimental spinal cord sectionsR Roy-Camille, J M Derlon, G Saillant, et al.
Neuro-Chirurgie|January 1, 1978
[Experimental transection of the spinal cord (author's transl)]J M Derlon, R Roy-Camille, G Saillant, et al.
Cancer Research|April 15, 1990
Monoclonal antibodies against native ant denatured forms of estrogen-induced breast cancer protein (BCEI/pS2) obtained by expression in Escherichia coliJ F Prud'homme, A Jolivet, M F Pichon, et al.
European Journal of Gynaecological Oncology|February 26, 1998
Cancer of the uterine cervix: sensitivity and specificity of serum Cyfra 21.1 determinationsN Callet, C C Cohen-Solal Le Nir, E Berthelot, et al.
The Pediatric Infectious Disease Journal|November 5, 1998
Pathogens isolated during treatment failures in otitisP Gehanno, L N'Guyen, M Derriennic, et al.
The International Journal of Biological Markers|January 11, 2003
Prognostic value of CA 15.3 kinetics for metastatic breast cancerB De La Lande, K Hacene, J L Floiras, et al.
The International Journal of Biological Markers|April 14, 2004
Serum HER-2 extracellular domain: relationship with clinicobiological presentation and prognostic value before and after primary treatment in 701 breast cancer patientsM Saghatchian, S Guepratte, K Hacene, et al.
The Journal of Infectious Diseases|May 1, 1989
In vivo selection of a cephamycin-resistant, porin-deficient mutant of Klebsiella pneumoniae producing a TEM-3 beta-lactamaseB Pangon, C Bizet, A Buré, et al.
Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine|October 29, 2000
Comparison of Cyfra 21-1 and SCC assays in head and neck tumoursA Banal, K Hacene, E Berthelot-Ruff, et al.
Pageof 8